SHENYANG, China, April 23, 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaudited first quarter 2012 results on Monday, May 14, 2012 at 8:00am (China Standard Time).
Following the earnings announcement, 3SBio's senior management will host a conference call on Monday, May 14, 2012 8:00pm (China Standard Time), 8:00am (US Eastern) 5:00am (US Pacific) to discuss its unaudited first quarter 2012 results and recent business activity. The conference call may be accessed using the dial-in numbers below:
Conference ID: 73956752
China landline: 800-819-0121
China mobile: 400-620-8038
Hong Kong : 852-2475-0994
United States: 718-354-1231
International toll-free dial-in:
Hong Kong: 800930346
United States: 1-866-519-4004
United Kingdom: 080-8234-6646
International toll dial-in: 65 6723 9381
Replay- Conference ID: 73956752
A telephone replay will be available two hours after the call until May 22, 2012 at:
United States: 1-866-214-5335
A replay of the webcast will be available within one hour after the conclusion of the call.
About 3SBio Inc.3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information. Investor ContactsBo Tan
Tom FolinsbeeChief Financial Officer
Director of Investor Relations3SBio Inc.
3SBio Inc.Tel: + 86 24 2581-1820
Tel: + 852 8191-6991ir@3SBio.com
|SOURCE 3SBio Inc.|
Copyright©2010 PR Newswire.
All rights reserved